Core Viewpoint - Investors are selling off software stocks due to fears over AI disruption, creating buying opportunities for high-quality businesses [1] Group 1: Company Overview - Doximity, a social feed and software provider for doctors, has seen its stock fall by 66% in the past year, trading close to an all-time low [2] - The company has a market cap of $4.7 billion, with a current stock price of $25.57 and a 52-week range of $23.66 to $76.51 [3] - Doximity began as a social network for medical professionals, allowing them to receive healthcare news and collaborate in a HIPAA-compliant manner [3] Group 2: Business Model - Doximity generates revenue through sponsorships from pharmaceutical companies, with 126 customers spending over $500,000 annually on the platform [4] - Approximately 85% of physicians in the U.S. use Doximity, indicating a strong market presence with little competition [4] Group 3: Growth Potential - The company is expanding into new software tools, including the DoxGPT AI assistant, which is expected to increase user engagement and revenue over time [5] - Revenue growth has been significant, increasing by 448% since March 2020, although it has slowed to 10% year-over-year growth last quarter [7] - Doximity has a strong EBIT margin of 38.5%, indicating best-in-class profitability for a software provider [8] Group 4: Investment Consideration - With a price-to-earnings ratio of 21, Doximity may present a growth stock opportunity amidst the current software market dip driven by AI fears [8]

Core Viewpoint - Piper Sandler has raised its price target on Doximity Inc. to $42 from $40 while maintaining an Overweight rating, indicating a positive outlook on the company's stock performance [1] Group 1: Doximity's AI Tool Suite - Insights from a demonstration led by CEO Jeff Tangney highlighted the strengths of Doximity's AI tool suite, particularly DoxGPT, which is noted for its integration within the Doximity ecosystem, the quality and accuracy of clinical reference responses, and a strong evidence base supporting its medical AI capabilities [2] - A new feature called PeerCheck allows healthcare professionals to efficiently transition from clinical questions to citations and original sources, enhancing the utility of DoxGPT [2] Group 2: Market Potential and Stock Valuation - As AI tools like Scribe and DoxGPT become integrated into Doximity's workflow platform, there is an expectation of increased adoption among individual healthcare professionals and enterprise contracts with hospitals and health systems, creating a virtuous cycle [3] - Piper Sandler believes the market is undervaluing DoxGPT's potential, especially following the fiscal third-quarter 2026 EPS results, leading to an updated price target of $42 based on a 20.0x multiple applied to slightly higher calendar 2027 adjusted EBITDA estimates [4]

Unity’s own users have access to a range of interactive connections, including livestreams and discussions, to get the most out of the platform by finding out what other users are doing with it. It’s part of Unity’s overall commitment to providing transparency in the service.A short trip through Unity’s website shows that the company can offer a wide range of services, including 2D and 3D game creation, user acquisition apps so that creators can bring in an audience, and monetization apps that allow creator ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Insights - The analyst previously held a hold rating for Doximity Inc. (DOCS) due to high valuation and poor guidance, but the current assessment of the core business suggests potential for improvement [1] Company Analysis - The investment approach emphasizes understanding core economics, including competitive moat, unit economics, reinvestment runway, and management quality, which are crucial for long-term free cash flow generation and shareholder value creation [1] - The focus is on sectors with strong secular tailwinds, indicating a preference for industries that are expected to grow over time [1] Investment Philosophy - The analyst is a self-educated investor with 10 years of experience, currently managing personal funds sourced from friends and family [1] - The motivation for sharing insights on Seeking Alpha is to provide valuable analysis and receive feedback from other investors, aiming to highlight what drives long-term equity value [1]

Core Insights - William Blair Investment Management reduced its position in Doximity by 372,184 shares, valued at approximately $20.89 million, during Q4 2025, resulting in a decrease of $184.77 million in the quarter-end value of its Doximity stake [1][2] Company Overview - Doximity operates a cloud-based digital platform that connects U.S. medical professionals, serving healthcare and pharmaceutical clients [5] - As of February 6, 2026, Doximity's stock price was $27.73, with a market capitalization of $5.09 billion, revenue of $637.78 million, and net income of $239.40 million [4] Stock Performance - Doximity shares have declined by 66% year-over-year, significantly underperforming the S&P 500 by 82 percentage points [3] - The stock is currently trading at 17 times free cash flow, marking its lowest-ever valuation [8] Revenue and Growth - Doximity generates revenue primarily from pharmaceutical manufacturers and healthcare systems, targeting physicians and medical organizations [7] - Sales growth has slowed from 23% in Q3 of the previous year to 10% this year, with management guiding for only 4% growth in Q4 [9]

Core Viewpoint - Doximity Inc (NYSE:DOCS) is facing significant stock price volatility, with recent analyst ratings reflecting mixed sentiments about its future performance [1][2][3][4][6] Stock Performance - Doximity's stock opened at $23.69 after closing at $33.32, with the last traded price at $25.50, indicating a notable decline [2] - The current stock price is $27.73, down 16.78% from a previous high of $85.21 over the past year, with a trading range between $23.66 and $27.88 [4][6] - The trading volume today reached 22.18 million shares, suggesting strong investor interest despite the price fluctuations [5] Analyst Ratings - Canaccord Genuity set a price target of $34 for DOCS, indicating a potential upside of 22.61% from its current price [1] - Wall Street Zen downgraded DOCS from "buy" to "hold," while Weiss Ratings maintained a "hold (c+)" rating [2] - Conversely, Wells Fargo upgraded DOCS to "overweight" with a target price of $55.00, and both the Royal Bank Of Canada and Needham and Company LLC upgraded to "moderate buy" [3][6] Market Capitalization - Doximity's market capitalization is approximately $5.2 billion, reflecting its position in the healthcare technology sector [5]

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 46 cents for Q3 fiscal 2026, a 2.2% increase year over year, exceeding the Zacks Consensus Estimate by 4.5% [2] - The company's revenues for the quarter reached $185.1 million, marking a 10% year-over-year growth and surpassing the Zacks Consensus Estimate by 2.3% [3] Financial Performance - Subscription revenues amounted to $175.4 million, up 8.1% year over year, driven by a 112% net revenue retention rate and growth in large accounts [4] - Other revenues increased significantly by 52.6% year over year to $9.7 million [4] - Gross profit rose 7.7% year over year to $166.4 million, but gross margin contracted by 170 basis points to 89.9% [5] - Operating profit totaled $71.9 million, reflecting a 10% decline from the prior year, with operating margin contracting 855 basis points to 38.9% [6] Cash Position - Doximity ended Q3 fiscal 2026 with cash and cash equivalents of $64.8 million, down from $169.2 million at the end of Q2 [7] - Cumulative net cash provided by operating activities was $216.9 million, compared to $174.8 million a year ago [7] Guidance - For Q4 fiscal 2026, Doximity expects revenues between $143 million and $144 million, below the Zacks Consensus Estimate of $149.8 million [10] - The full fiscal year revenue outlook has been narrowed to between $642.5 million and $643.5 million, compared to the previous range of $640 million to $646 million, also below the consensus estimate of $645.3 million [10] Growth Drivers - Doximity experienced strong platform momentum with 3 million registered members, reaching over 85% of U.S. physicians [12] - Engagement metrics showed record highs, with significant increases in active users and workflow solutions [13] - AI adoption was a key growth driver, with over 300,000 prescribers using Doximity's AI tools during the quarter [14]

Core Viewpoint - Doximity's shares fell 24% following the release of third-quarter earnings, despite exceeding sales and earnings expectations, due to conservative guidance for 4% revenue growth in Q4 [1] Financial Performance - Doximity reported a sales growth decline from 23% in Q3 last year to 10% in Q3 this year, with net income decreasing from $75 million in Q3 2025 to $62 million this year [1] - Marketing expenses rose by 27%, and significant investments were made in AI infrastructure [1] Market Dynamics - Pharmaceutical companies, key customers of Doximity, are facing industry-specific challenges, leading to delayed bookings as they await clarity on most-favored-nation agreements [2] - The sales slowdown is viewed as a short-term issue rather than a long-term problem, with indications of improved bookings growth in January [2] AI Adoption and Future Outlook - Over 100 top U.S. health systems have begun using Doximity's AI products, with over 300,000 prescribers engaged in Q3 [6] - Doximity did not include AI revenue in its guidance, but the full launch of its commercial AI suite later this year could enhance growth rates and margins [6] - The company is currently trading at 17 times free cash flow and is widely used by 85% of U.S. physicians [6]

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a digital healthcare platform that integrates care delivery, data, and fulfillment into a consumer-facing ecosystem, enhancing personalization and continuity of care through proprietary technology [1][7] Group 1: Platform Development - The platform is evolving from episodic treatment to a proactive, data-driven model, with the launch of Labs for longitudinal biomarker tracking that informs provider action plans [2][7] - Investments in artificial intelligence (AI) and platform infrastructure are aimed at improving diagnostics, treatment matching, and care orchestration, positioning software and data as core differentiators [2][3] Group 2: Strategic Initiatives - The acquisition of YourBio Health introduces patented blood sampling technology, allowing for better integration of diagnostics with digital care delivery [3] - Ongoing investments in technology and AI capabilities are designed to enhance personalized care through proprietary systems and data feedback loops [3] Group 3: Market Performance - Hims & Hers shares have decreased by 44.8% over the past year, underperforming the industry decline of 35.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.9X, lower than the industry average of 3.7X and its three-year median of 2.6X [9] Group 4: Earnings Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 suggests an 85.2% improvement from 2024 [9] - Current estimates for the upcoming quarters indicate a potential recovery, with EPS expected to rise from 0.50 in 2025 to 0.58 in 2026 [10]